Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin + Irinotecan Liposome HAIC + 5-FU/LV or S-1 for Pancreatic Cancer Liver Metastasis
NCT06538623Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in pancreatic cancer (PC), sponsored by Ruijin Hospital. Started Aug 2024; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06538623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538623.